In August 2013, Compugen entered into a collaboration and license agreement with Bayer for the research, development, and commercialization of immuno-oncology therapeutics against novel targets identified by Compugen. The companies collaborated to develop BAY 1905254, the lead antibody targeting ILDR2, a novel B7/CD28-like immune checkpoint target. BAY 1905254 is currently being evaluated in a Phase 1 study in patients with advanced solid tumors. The study an open-label, dose escalation study designed to evaluate the safety and tolerability of BAY 1905254. First patient dosing was in September 2018 and the Phase 1 study is currently enrolling patients in the United States. For additional information on the Phase 1 study click here. Bayer now controls all clinical development and commercialization activities worldwide.
Compugen has received $25 million in upfront and preclinical milestone payments, and is eligible to receive over $250 million in total milestone payments, as well as tiered royalties on global sales.
“At Bayer HealthCare, we are impressed with Compugen’s ability to identify novel immune checkpoints through the use of their predictive discovery infrastructure, and are pleased to collaborate with their professional scientific team on therapeutic antibody development in the field of immuno-oncology.”
Karl Ziegelbauer, Head of Global Therapeutic Research Groups, Bayer